Form 4: Prelude Therapeutics CMO Jane Huang Reports Routine RSU Vesting and Tax Withholding
Insider Transaction Report
Prelude Therapeutics Inc.'s President and Chief Medical Officer, Jane Huang, reported the vesting of 9,375 Restricted Stock Units and the subsequent disposition of 3,355 shares for tax withholding purposes.
Summary
- Jane Huang, President and Chief Medical Officer of Prelude Therapeutics Inc. (PRLD), reported transactions related to her beneficial ownership of company common stock.
- On July 4, 2025, 9,375 shares of common stock were acquired upon the vesting of Restricted Stock Units (RSUs).
- Following this acquisition, Jane Huang's direct beneficial ownership of common stock increased to 84,252 shares.
- Concurrently, 3,355 shares of common stock were disposed of on July 4, 2025, at a price of $0.7939 per share.
- This disposition was to satisfy tax withholding obligations associated with the RSU vesting.
- After the tax-related disposition, Jane Huang's direct beneficial ownership of common stock was 80,897 shares.
- The RSUs were originally granted on May 2, 2022, with a vesting schedule that included 1/4 of the total shares vesting on April 4, 2023, and 1/16 of the remaining shares vesting quarterly thereafter, contingent on continued service.
- Following these transactions, Jane Huang beneficially owns 28,125 unvested Restricted Stock Units.
Sentiment
Score: 5
Explanation: The document reports a routine insider transaction (RSU vesting and tax withholding) which is a neutral event. It does not contain information that would significantly alter the perception of the company's financial health or operational performance.
Future Outlook
N/A. This document is a Form 4 filing reporting insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
N/A. This Form 4 filing details a routine insider transaction (RSU vesting and tax withholding) and does not provide information relevant to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization | Jane Huang, President and CMO, granted a Power of Attorney to Prelude Therapeutics Incorporated's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer. This authorizes them to execute and file Section 16 reports (Forms ID, 3, 4, and 5) on her behalf for transactions in company securities. | 2025-07-07 | This is a standard corporate governance practice that streamlines the process for insiders to comply with SEC reporting requirements for their stock transactions, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders: Provides transparency regarding insider stock ownership changes, which is a routine disclosure for publicly traded companies. The transaction itself is a standard compensation event and does not indicate a change in company strategy or performance.
Next Steps
- Remaining RSUs will continue to vest quarterly at a rate of 1/16 of the original remaining shares, subject to Jane Huang's continued service to the Issuer.
Key Dates
| Date | Description |
|---|---|
| 2022-05-02 | Date Restricted Stock Units (RSUs) were granted to Jane Huang. |
| 2023-04-04 | First vesting date for 1/4 of the total RSUs granted to Jane Huang. |
| 2025-07-04 | Date of RSU vesting and subsequent common stock acquisition and tax-related disposition. |
| 2025-07-07 | Date Jane Huang executed the Power of Attorney. |
| 2025-07-08 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Prelude Therapeutics Inc., PRLD, Jane Huang, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Ownership, Tax Withholding, Corporate Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.